Summary

• Study director: William Jagust, MD and Gil Rabinovici, MD [1]
• Sponsors: National Institutes of Health (NIH) and the Alzheimer’s Association
• Recruiting?: Yes
• Official study title: Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
• Conditions studied: Behavioral variant frontotemporal dementia (bvFTD) [2], semantic dementia (SD) [3], progressive nonfluent aphasia (PNFA) [4], Alzheimer's disease (AD) [5], logopenic progressive aphasia (LPA) [6], primary progressive aphasia (PPA) [6], posterior cortical atrophy (PCA) and corticobasal degeneration (CBD) [7]
• Purpose: The purpose of this study is to determine if amyloid PET imaging with Pittsburgh Compound-B (PIB) can improve diagnostic accuracy in discriminating between AD and FTD.